Juncture Wealth Strategies LLC raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 109.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 12,208 shares of the company's stock after acquiring an additional 6,379 shares during the period. Juncture Wealth Strategies LLC's holdings in Amphastar Pharmaceuticals were worth $343,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $35,000. US Bancorp DE lifted its holdings in Amphastar Pharmaceuticals by 49.5% in the second quarter. US Bancorp DE now owns 2,023 shares of the company's stock valued at $70,000 after acquiring an additional 670 shares during the period. Point72 Hong Kong Ltd bought a new position in Amphastar Pharmaceuticals in the first quarter valued at about $74,000. Nisa Investment Advisors LLC increased its position in Amphastar Pharmaceuticals by 22.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,550 shares of the company's stock worth $89,000 after buying an additional 460 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in Amphastar Pharmaceuticals by 114.4% in the first quarter. Captrust Financial Advisors now owns 2,770 shares of the company's stock worth $99,000 after buying an additional 1,478 shares in the last quarter. Institutional investors own 63.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Jefferies Financial Group downgraded Amphastar Pharmaceuticals to a "buy" rating and set a $36.00 price target for the company. in a research note on Friday, October 21st. StockNews.com upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, November 19th. Finally, Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $43.00 to $40.00 and set an "overweight" rating for the company in a research note on Tuesday, October 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $39.00.

Amphastar Pharmaceuticals Trading Down 1.2 %

Amphastar Pharmaceuticals Company Profile

(Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Read More

• Get a free copy of the StockNews.com research report on Amphastar Pharmaceuticals (AMPH)
• Which Two Bluechip Tech Companies Have Raised Their Guidance?
• Should You Worry About Elon Musk Selling His Tesla Shares?
• Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
• This is no Time to Buy Lennar but the Time is Coming
• Game-Changing News For Mullen Automotive

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating).

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.